<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0">
   <channel>
      <title>Alta Partners</title>
      <link>http://www.altapartners.com/</link>
      <description>Alta Partners news.</description>
      <language>en</language>
      <copyright>Copyright 2006</copyright>
      <lastBuildDate>Tue, 19 Aug 2008 00:00:00 +0800</lastBuildDate>
      <generator>http://www.php.net/</generator>
      <docs>http://blogs.law.harvard.edu/tech/rss</docs> 
        
            <item>
         <title><![CDATA[ATS Receives CE Mark, ISO Certification for CryoMaze
]]></title>
         <description><![CDATA[
    <p>Source: Medical Device Daily</p>
A Medical Device Daily Staff Report
ATS Medical (Minneapolis), a provider of cardiac surgery products and services, reported that it has received ISO certification for its quality systems to manufacture and CE-mark approval to distribute its CryoMaze cardiac ablation products in the European Union.
<br /><br /> 
These approvals, in combination with the completion of transfer of the U.S. 510k rights and validation of the manufacturing processes, enable the company to sell the ATS product line ... 
        ]]></description>
         <link>http://www.altapartners.com/news_detail.php?id=320</link>
         <guid>http://www.altapartners.com/news_detail.php?id=320</guid>
         <pubDate>Tue, 19 Aug 2008 00:00:00 +0800</pubDate>
      </item>
        
            <item>
         <title><![CDATA[Ethicon to Acquire SurgRx for an Undisclosed Amount]]></title>
         <description><![CDATA[
    <p>By Amanda Pedersen, Staff Writer</p>
<p>Source: Medical Device Daily</p>
After raising about $83 million in venture funding, SurgRx (Redwood City, California), developer of a vessel fusion system used in electrosurgical devices, has agreed to be acquired by Ethicon Endo-Surgery (Cincinnati), a Johnson & Johnson (New Brunswick, New Jersey) company.
<br /><br />
Financial terms of the deal were not disclosed and the deal is subject to approval by both U.S. and overseas regulators.
<br /><br />
Ethicon said the acquisition would provide it with a new energy ... 
        ]]></description>
         <link>http://www.altapartners.com/news_detail.php?id=319</link>
         <guid>http://www.altapartners.com/news_detail.php?id=319</guid>
         <pubDate>Wed, 13 Aug 2008 00:00:00 +0800</pubDate>
      </item>
        
            <item>
         <title><![CDATA[Cara Therapeutics Secures $12.3 Million In Series C Extension Financing
]]></title>
         <description><![CDATA[
    <p><a href='http://www.caratherapeutics.com/press-releases.php#press7'>http://www.caratherapeutics.com/press-releases.php#press7</a></p> 
        ]]></description>
         <link>http://www.caratherapeutics.com/press-releases.php#press7</link>
         <guid>http://www.caratherapeutics.com/press-releases.php#press7</guid>
         <pubDate>Thu, 24 Jul 2008 00:00:00 +0800</pubDate>
      </item>
        
            <item>
         <title><![CDATA[Market Conditions Sour IPO Prospects For Some Firms – MDMA Panelists
]]></title>
         <description><![CDATA[
    <p>Source: The Gray Sheet</p>
Small medical device companies seeking new sources of funding are being cautioned by venture capitalist <strong>Guy Nohra, co-founder of Alta Partners, that now is a tough time to go public. 
<br /><br /> 
For "small concept" companies, a successful initial public offering is "just not going to happen" in the current weak stock market environment, Nohra suggested at the Medical Device Manufacturers Association meeting in Washington, D.C., June 13. 
<br /><br /> 
Nohra was among participants ... 
        ]]></description>
         <link>http://www.altapartners.com/news_detail.php?id=316</link>
         <guid>http://www.altapartners.com/news_detail.php?id=316</guid>
         <pubDate>Wed, 23 Jul 2008 00:00:00 +0800</pubDate>
      </item>
        
            <item>
         <title><![CDATA[MacroGenics Boosts Anticancer Pipeline with Raven Acquisition]]></title>
         <description><![CDATA[
    <p>By Trista Morrison <br />
Staff Writer</p>
<p>Source: BioWorld Today</p>
In a deal to be announced Thursday morning, MacroGenics Inc. is bolstering its anticancer antibody pipeline with the acquisition of Raven Biotechnologies Inc. 
<br /><br />
The two privately held companies did not disclose specific financial terms for the all-stock deal. MacroGenics' headquarters in Rockville, Md. and Raven's facilities in South San Francisco will both remain operational, although there will be a small reduction in staff to "eliminate redundancies," MacroGenics President and ... 
        ]]></description>
         <link>http://www.altapartners.com/news_detail.php?id=312</link>
         <guid>http://www.altapartners.com/news_detail.php?id=312</guid>
         <pubDate>Thu, 17 Jul 2008 00:00:00 +0800</pubDate>
      </item>
 
  </channel>
</rss>
     